Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a slight increase of +0.17% on February 24, 2025, underperforming the CSI 300 index by 0.84 percentage points, ranking 23rd among 31 sub-industries [4]. - Notable performers within the pharmaceutical sub-industries included in vitro diagnostics (+1.36%), other biological products (+1.06%), and pharmaceutical distribution (+1.04%), while medical research outsourcing (-1.39%), offline pharmacies (+0.37%), and medical devices (+0.49%) lagged behind [4]. - Savara's Molbreevi received priority review status from the FDA for treating autoimmune PAP, potentially becoming the first drug approved for this condition in the US and Europe [5]. - Three-Six Health reported a significant revenue increase of 251.81% year-on-year, reaching 4.199 billion yuan, with a net profit growth of 317.09% to 2.939 billion yuan [5]. - Aidi Pharmaceutical's revenue grew by 72.49% year-on-year to 721 million yuan, although it still reported a net loss of 19.73 million yuan [6]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceutical Therapies: Neutral [3]

Group 1 - The company has received the Certificate of Suitability (CEP) for the active pharmaceutical ingredient Ticagrelor from the European Directorate for the Quality of Medicines & HealthCare (EDQM), indicating compliance with European pharmacopoeia standards [1][2] - Ticagrelor is used for the treatment of acute coronary syndrome (ACS) and is known to reduce the incidence of cardiovascular death, myocardial infarction, and stroke in patients with a history of myocardial infarction [1] - The global sales volume of Ticagrelor active pharmaceutical ingredient is projected to be approximately 171,705.29 kilograms for 2024, with an estimated 143,714.60 kilograms sold from January to September 2025 [1] Group 2 - The CEP certification signifies recognition of the quality of the active pharmaceutical ingredient in the European market, enhancing the company's qualifications to enter the EU and other markets that recognize the CEP certificate [2] - The international active pharmaceutical ingredient business is subject to fluctuations in overseas market conditions and exchange rates, which may impact the company's operations [2]

Group 1 - The company, Zhejiang Haizheng Pharmaceutical Co., Ltd., has received the Certificate of Suitability (CEP) for the active pharmaceutical ingredient Ticagrelor from the European Directorate for the Quality of Medicines & HealthCare (EDQM) [1][2] - The CEP certificate indicates that the quality of Ticagrelor is recognized and approved for entry into the European Union and other markets that acknowledge the CEP certification, which positively impacts the company's international market expansion [2] - The global sales volume of Ticagrelor active pharmaceutical ingredient is projected to be approximately 171,705.29 kilograms for 2024, with about 143,714.60 kilograms sold from January to September 2025 [1]

Group 1 - Hengyu Environmental reported a revenue of 294 million yuan for 2025, an increase of 89.87%, and a net profit of 35.93 million yuan, up 106.25% year-on-year [1] - Yongxi Electronics achieved a revenue of 4.4 billion yuan in 2025, a growth of 21.92%, with a net profit of 82.24 million yuan, reflecting a year-on-year increase of 23.99% [2] - Zhongwei Semiconductor reported a revenue of 1.122 billion yuan for 2025, a 23.09% increase, and a net profit of 285 million yuan, up 108.05% year-on-year [3] - Sry New Materials achieved a revenue of 1.564 billion yuan in 2025, a growth of 17.66%, with a net profit of 154 million yuan, reflecting a year-on-year increase of 35.04% [14] - Jiaokong Technology reported a revenue of 2.537 billion yuan for 2025, a growth of 16.08%, and a net profit of 156 million yuan, up 86.13% year-on-year [15] - SanSheng Guojian reported a revenue of 4.199 billion yuan for 2025, a significant increase of 251.81%, with a net profit of 2.939 billion yuan, up 317.09% year-on-year [30] Group 2 - Aidi Pharmaceutical reported a revenue of 721 million yuan for 2025, a growth of 72.49%, but incurred a net loss of 19.73 million yuan, reducing losses from 142 million yuan in the previous year [5] - Weidao Nano reported a revenue of 2.632 billion yuan for 2025, a decrease of 2.52%, with a net profit of 213 million yuan, down 6.12% year-on-year [9] - Wens Foodstuff Group reported a revenue of 103.884 billion yuan for 2025, a decline of 1.67%, with a net profit of 5.235 billion yuan, down 43.59% year-on-year [29] - Supor reported a revenue of 22.772 billion yuan for 2025, a growth of 1.54%, with a net profit of 2.097 billion yuan, down 6.58% year-on-year [33] Group 3 - ShaoNeng Co. signed a significant operational contract worth 22 million yuan for a biomass power generation project [6] - Shunlian Bio plans to use 237 million yuan to acquire controlling interest in a joint venture, increasing its stake from 16.99% to 51% [7] - Huason Pharmaceutical's subsidiary received clinical trial approval for an innovative drug, indicating progress in its product pipeline [8] - Xinyang Technology's subsidiary received a medical device registration certificate, enhancing its product offerings [10][11] - Yida Co. obtained an investment project filing certificate for a chemical production project with a total investment of 642 million yuan [12]

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received the Certificate of Suitability to Monograph of European Pharmacopoeia (CEP) for its raw material drug Ticagrelor from the European Directorate for the Quality of Medicines & HealthCare (EDQM), indicating the quality recognition of this drug in the European market and enhancing the company's potential for international market expansion [1] Group 1 - The CEP certification for Ticagrelor signifies the drug's suitability for treating Acute Coronary Syndrome (ACS) and its effectiveness in reducing cardiovascular death, myocardial infarction, and stroke in ACS patients or those with a history of myocardial infarction [1] - The original manufacturer of Ticagrelor is AstraZeneca, highlighting the competitive landscape in the pharmaceutical industry [1] - The certification allows the raw material to enter the EU market and other markets that recognize the CEP certificate, which is expected to have a positive impact on the company's international market expansion efforts [1]

Core Viewpoint - The company has received the European Pharmacopoeia suitability certificate for the active pharmaceutical ingredient Ticagrelor, enabling it to enter the EU market and other markets that recognize the CEP certificate, which positively impacts its international market expansion [1] Group 1: Certification and Market Impact - The receipt of the certificate from the European Medicines Agency (EDQM) signifies that the product is qualified to enter the EU and other markets recognizing the CEP certificate [1] - The certification is expected to facilitate the company's further expansion into international markets [1] Group 2: Product Information - Ticagrelor is used for the treatment of acute coronary syndrome, with the original manufacturer being AstraZeneca [1] - Projected global sales volume for 2024 is approximately 171,705.29 kilograms, while for the period of January to September 2025, it is estimated at around 143,714.60 kilograms [1] Group 3: Application Timeline - The company submitted the application to EDQM on December 28, 2023, and recently received the CEP certificate [1]

Core Viewpoint - The company, Tonghua Dongbao Pharmaceutical, has received a revised Certificate of Suitability (CEP) for its Ticagrelor active pharmaceutical ingredient from the European Directorate for the Quality of Medicines (EDQM), effective from September 12, 2025, due to the addition of a new production workshop [1] Group 1 - The revised CEP indicates compliance with European pharmacopoeia standards, which is crucial for market access in Europe [1] - The change in the certificate is a strategic move to enhance production capacity and meet regulatory requirements [1] - The new production facility is expected to support the company's growth in the European market [1]

Core Viewpoint - The company, Tonghe Pharmaceutical, has received an updated Certificate of Suitability (CEP) from the European Medicines Agency for its raw material drug, Ticagrelor, due to the addition of a new production facility, effective from September 12, 2025 [1] Group 1: Company Information - Tonghe Pharmaceutical announced the receipt of the updated CEP for Ticagrelor, a novel selective small-molecule anticoagulant [1] - The updated certificate is a result of the company's expansion with a new production workshop [1] Group 2: Product Details - Ticagrelor is designed to block platelet activation, used for treating acute coronary syndrome patients, and aims to reduce the occurrence of thrombotic cardiovascular diseases [1] - The drug is characterized by its rapid and potent effects [1]

Group 1 - The company, Tonghe Pharmaceutical (300636.SZ), has received a revised Certificate of Suitability (CEP) for the raw material drug Ticagrelor from the European Directorate for the Quality of Medicines (EDQM) [1] - The revision is due to the addition of a new production workshop, and the certification scope includes Ticagrelor raw material [1] - The revised certificate will be effective from September 12, 2025 [1]

Core Viewpoint - The company has received a revised Certificate of Suitability (CEP) for the active pharmaceutical ingredient Ticagrelor from the European Directorate for the Quality of Medicines (EDQM), effective from September 12, 2025, due to the addition of a new production facility [1]. Group 1 - The company announced the receipt of the updated CEP for Ticagrelor active pharmaceutical ingredient [1]. - The revision of the CEP is primarily due to the establishment of a new production workshop [1]. - The effective date for the revised certificate is set for September 12, 2025 [1].